• Je něco špatně v tomto záznamu ?

A Comparison of the Neuroprotective and Reactivating Efficacy of a Novel Bispyridinium Oxime K870 with Commonly Used Pralidoxime and the Oxime HI-6 in Tabun-Poisoned Rats

J. Kassa, J. Hatlapatková, J. Žďárová Karasová, V. Hepnarová, F. Caisberger, J. Pejchal

. 2021 ; 64 (3) : 145-152. [pub] 20211111

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21029384

AIM: The comparison of neuroprotective and central reactivating effects of the oxime K870 in combination with atropine with the efficacy of standard antidotal treatment in tabun-poisoned rats. METHODS: The neuroprotective effects of antidotal treatment were determined in rats poisoned with tabun at a sublethal dose using a functional observational battery 2 h and 24 h after tabun administration, the tabun-induced brain damage was investigated by the histopathological evaluation and central reactivating effects of oximes was evaluated by the determination of acetylcholinesterase activity in the brain using a standard spectrophotometric method. RESULTS: The central reactivating efficacy of a newly developed oxime K870 roughly corresponds to the central reactivating efficacy of pralidoxime while the ability of the oxime HI-6 to reactivate tabun-inhibited acetylcholinesterase in the brain was negligible. The ability of the oxime K870 to decrease tabun-induced acute neurotoxicity was slightly higher than that of pralidoxime and similar to the oxime HI-6. These results roughly correspond to the histopathological evaluation of tabun-induced brain damage. CONCLUSION: The newly synthesized oxime K870 is not a suitable replacement for commonly used oximes in the antidotal treatment of acute tabun poisonings because its neuroprotective efficacy is only slightly higher or similar compared to studied currently used oximes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21029384
003      
CZ-PrNML
005      
20211227140321.0
007      
ta
008      
211206s2021 xr f 000 0|eng||
009      
AR
024    7_
$a 10.14712/18059694.2021.25 $2 doi
035    __
$a (PubMed)34779379
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Kassa, Jiří, $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic. kassa@pmfhk.cz $d 1956- $7 mzk2003181395
245    12
$a A Comparison of the Neuroprotective and Reactivating Efficacy of a Novel Bispyridinium Oxime K870 with Commonly Used Pralidoxime and the Oxime HI-6 in Tabun-Poisoned Rats / $c J. Kassa, J. Hatlapatková, J. Žďárová Karasová, V. Hepnarová, F. Caisberger, J. Pejchal
520    9_
$a AIM: The comparison of neuroprotective and central reactivating effects of the oxime K870 in combination with atropine with the efficacy of standard antidotal treatment in tabun-poisoned rats. METHODS: The neuroprotective effects of antidotal treatment were determined in rats poisoned with tabun at a sublethal dose using a functional observational battery 2 h and 24 h after tabun administration, the tabun-induced brain damage was investigated by the histopathological evaluation and central reactivating effects of oximes was evaluated by the determination of acetylcholinesterase activity in the brain using a standard spectrophotometric method. RESULTS: The central reactivating efficacy of a newly developed oxime K870 roughly corresponds to the central reactivating efficacy of pralidoxime while the ability of the oxime HI-6 to reactivate tabun-inhibited acetylcholinesterase in the brain was negligible. The ability of the oxime K870 to decrease tabun-induced acute neurotoxicity was slightly higher than that of pralidoxime and similar to the oxime HI-6. These results roughly correspond to the histopathological evaluation of tabun-induced brain damage. CONCLUSION: The newly synthesized oxime K870 is not a suitable replacement for commonly used oximes in the antidotal treatment of acute tabun poisonings because its neuroprotective efficacy is only slightly higher or similar compared to studied currently used oximes.
650    _2
$a acetylcholinesterasa $7 D000110
650    _2
$a zvířata $7 D000818
650    _2
$a antidota $x farmakologie $7 D000931
650    12
$a chemické bojové látky $x toxicita $7 D002619
650    _2
$a cholinesterasové inhibitory $x farmakologie $7 D002800
650    12
$a reaktivátory cholinesterázy $x farmakologie $7 D002801
650    12
$a organofosfáty $7 D010755
650    12
$a oximy $x farmakologie $7 D010091
650    12
$a jedy $7 D011042
650    _2
$a pralidoximové sloučeniny $7 D011220
650    12
$a pyridinové sloučeniny $x farmakologie $7 D011726
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hatlapatková, Jana $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic $7 xx0267752
700    1_
$a Žďárová Karasová, Jana, $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic $d 1982- $7 xx0099787
700    1_
$a Hepnarová, Vendula $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic $7 xx0216882
700    1_
$a Caisberger, Filip $u Neurology, University Hospital Hradec Králové, Hradec Králové, Czech Republic $7 xx0238434
700    1_
$a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic $7 xx0102560
773    0_
$w MED00010947 $t Acta Medica (Hradec Kralove) $x 1805-9694 $g Roč. 64, č. 3 (2021), s. 145-152
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34779379 $y Pubmed
910    __
$a ABA008 $b A 3077 $c 1072 $y p $z 0
990    __
$a 20211206 $b ABA008
991    __
$a 20211227140320 $b ABA008
999    __
$a ok $b bmc $g 1731384 $s 1149937
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 64 $c 3 $d 145-152 $e 20211111 $i 1805-9694 $m Acta Medica $n Acta Med. (Hradec Král.) $x MED00010947
LZP    __
$b NLK138 $a Pubmed-20211206

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace